Idiopathic Pulmonary Fibrosis Clinical Diagnostic Scoring System Validated
The Fairfax idiopathic pulmonary fibrosis (IPF) clinical score was an accurate tool for estimating probability of IPF in patients with interstitial lung disease.
Idiopathic Pulmonary Fibrosis
Valganciclovir Plus Pirfenidone Appears Safe, Tolerable in Idiopathic Pulmonary Fibrosis
There were no limiting safety or tolerability signals identified with the addition of valganciclovir to pirfenidone therapy in patients with idiopathic pulmonary fibrosis.
Trials Evaluating Ziritaxestat for Idiopathic Pulmonary Fibrosis Discontinued
Ziritaxestat is an investigational autotaxin inhibitor.
Idiopathic Pulmonary Fibrosis May Be Associated With Gastroesophageal Reflux Disease
Patients with idiopathic pulmonary fibrosis (IPF) have nearly double the risk of having gastroesophageal reflux disease (GERD) compared with the general population.
Diagnosing Hypersensitivity Pneumonitis: A New Clinical Practice Guideline
A multidisciplinary committee of international experts have released a new clinical practice guideline on the diagnosis of adult hypersensitivity pneumonitis, an immune-mediated inflammatory lung and small airway disease.
Nintedanib’s Adverse Event Profile in SSc-ILD Consistent With Safety, Tolerability in Idiopathic Pulmonary Fibrosis
Researchers characterized the safety and tolerability of nintedanib and the dose adjustments for adverse events in patients with systemic sclerosis-associated interstitial lung disease.
Pulmonary Fibrosis Awareness Month: Spotlight on the PFF Care Center Network
As a central goal of PF Awareness Month and their ongoing work, the Pulmonary Fibrosis Foundation aims to improve diagnostic delays and misdiagnoses in this patient population.
Bronchoalveolar Lavage Appears Safe, Well Tolerated in Idiopathic Pulmonary Fibrosis
In patients with COPD, lung methylation profiles differ according to the severity of airflow limitation and some epigenetic changes translate into specific gene expression changes in the lung.
Comparing Mortality Risks Between Idiopathic Pulmonary Fibrosis Treatments
In patients with idiopathic pulmonary fibrosis, treatment with pirfenidone was associated with a lower risk of mortality and acute respiratory-related hospitalizations than treatment with nintedanib.
Effect of COVID-19 on Pulmonary Fibrosis Clinical Trials: Expert Interview
Individuals with pulmonary fibrosis could develop more serious complications if infected with COVID-19, and those awaiting organ transplantation and other surgical interventions may face delays because of the pandemic.
-
Loading...
-
Loading...
Next post in Restrictive Lung Disease
